| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 仿制药原料药及中间体(元) | - | - | 1,066,156,907.91 | - | 1,269,211,569.45 |
| 制剂(元) | - | - | 42,778,016.85 | - | 10,152,917.11 |
| CMO(元) | - | - | 231,001,664.79 | - | 184,687,726.64 |
| 降血糖类原料药及中间体(元) | - | 87,693,630.16 | - | 110,847,268.86 | - |
| 抗凝血类原料药及中间体(元) | 158,220,586.93 | 350,409,718.93 | - | 204,257,534.88 | - |
| 降血压类原料及中间体(元) | 743,642,607.54 | 1,627,378,186.42 | - | 1,991,490,006.87 | - |
| 抗病毒原料及中间体(元) | - | 45,032,551.47 | - | 72,118,137.56 | - |
| 抗哮喘类原料及中间体(元) | - | 169,599,502.69 | - | 138,624,863.82 | - |
| 降血脂类原料药及中间体(元) | - | 58,751,048.93 | - | - | - |
| 其他(元) | - | 188,405,472.87 | 6,440,246.90 | 149,340,659.81 | 9,881,537.54 |
| 营业成本(元) | |||||
| 仿制药原料药及中间体(元) | - | - | 698,554,921.84 | - | 952,438,279.23 |
| 制剂(元) | - | - | 13,572,875.13 | - | 5,020,182.56 |
| CMO(元) | - | - | 95,488,745.04 | - | 93,943,391.38 |
| 降血糖类原料药及中间体(元) | - | - | - | - | - |
| 抗凝血类原料药及中间体(元) | 80,135,575.44 | 160,680,399.22 | - | 87,054,332.03 | - |
| 降血压类原料及中间体(元) | 480,961,621.19 | 1,001,580,220.71 | - | 1,469,321,890.66 | - |
| 抗病毒原料及中间体(元) | - | - | - | - | - |
| 抗哮喘类原料及中间体(元) | - | - | - | - | - |
| 降血脂类原料药及中间体(元) | - | - | - | - | - |
| 其他(元) | - | - | - | - | 8,386,868.30 |
| 毛利(元) | |||||
| 仿制药原料药及中间体(元) | - | - | 367,601,986.07 | - | 316,773,290.22 |
| 制剂(元) | - | - | 29,205,141.72 | - | 5,132,734.55 |
| CMO(元) | - | - | 135,512,919.75 | - | 90,744,335.26 |
| 降血糖类原料药及中间体(元) | - | - | - | - | - |
| 抗凝血类原料药及中间体(元) | 78,085,011.49 | 189,729,319.71 | - | 117,203,202.85 | - |
| 降血压类原料及中间体(元) | 262,680,986.35 | 625,797,965.71 | - | 522,168,116.21 | - |
| 抗病毒原料及中间体(元) | - | - | - | - | - |
| 抗哮喘类原料及中间体(元) | - | - | - | - | - |
| 降血脂类原料药及中间体(元) | - | - | - | - | - |
| 其他(元) | - | - | - | - | 1,494,669.24 |
| 毛利率(%) | |||||
| 仿制药原料药及中间体(%) | - | - | 34.48 | - | 24.96 |
| 制剂(%) | - | - | 68.27 | - | 50.55 |
| CMO(%) | - | - | 58.66 | - | 49.13 |
| 降血糖类原料药及中间体(%) | - | - | - | - | - |
| 抗凝血类原料药及中间体(%) | 49.35 | 54.14 | - | 57.38 | - |
| 降血压类原料及中间体(%) | 35.32 | 38.45 | - | 26.22 | - |
| 抗病毒原料及中间体(%) | - | - | - | - | - |
| 抗哮喘类原料及中间体(%) | - | - | - | - | - |
| 降血脂类原料药及中间体(%) | - | - | - | - | - |
| 其他(%) | - | - | - | - | 15.13 |
| 收入构成(%) | |||||
| 仿制药原料药及中间体(%) | - | - | 79.19 | - | 86.11 |
| 制剂(%) | - | - | 3.18 | - | 0.69 |
| CMO(%) | - | - | 17.16 | - | 12.53 |
| 降血糖类原料药及中间体(%) | - | 3.47 | - | 4.16 | - |
| 抗凝血类原料药及中间体(%) | 17.54 | 13.87 | - | 7.66 | - |
| 降血压类原料及中间体(%) | 82.46 | 64.39 | - | 74.68 | - |
| 抗病毒原料及中间体(%) | - | 1.78 | - | 2.70 | - |
| 抗哮喘类原料及中间体(%) | - | 6.71 | - | 5.20 | - |
| 降血脂类原料药及中间体(%) | - | 2.32 | - | - | - |
| 其他(%) | - | 7.45 | 0.48 | 5.60 | 0.67 |
| 毛利构成(%) | |||||
| 仿制药原料药及中间体(%) | - | - | 69.06 | - | 76.49 |
| 制剂(%) | - | - | 5.49 | - | 1.24 |
| CMO(%) | - | - | 25.46 | - | 21.91 |
| 降血糖类原料药及中间体(%) | - | 0.00 | - | 0.00 | - |
| 抗凝血类原料药及中间体(%) | 22.91 | 23.26 | - | 18.33 | - |
| 降血压类原料及中间体(%) | 77.09 | 76.74 | - | 81.67 | - |
| 抗病毒原料及中间体(%) | - | 0.00 | - | 0.00 | - |
| 抗哮喘类原料及中间体(%) | - | 0.00 | - | 0.00 | - |
| 降血脂类原料药及中间体(%) | - | 0.00 | - | - | - |
| 其他(%) | - | 0.00 | 0.00 | 0.00 | 0.36 |